Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Polycythemia Vera × Interferon-alpha × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 10 Carcinoma, Renal Cell 9 Kidney Neoplasms 7 Leukemia, Myeloid, Chronic-Phase 6 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6 Leukemia 6 Multiple Myeloma 4 Lymphoma, Mantle-Cell 3 Lymphoma 3 Rectal Neoplasms 2 Neoplasms, Plasma Cell 2 Lymphoma, Follicular 2 Waldenstrom Macroglobulinemia 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Hepatocellular 1

Interventions

Hydroxyurea 6 ruxolitinib 4 peginterferon alfa-2b 2 Phlebotomy 2 Early Intervention, Educational 2 Aspirin 2 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2 pomalidomide 1 peginterferon alfa-2a 1 liposomal amphotericin B 1 givinostat hydrochloride 1 givinostat 1 bomedemstat 1 anagrelide 1 Pipobroman 1 Pharmacogenomic Testing 1 Ondansetron 1 N(4)-oleylcytosine arabinoside 1 Morphine 1 Lenalidomide 1 Ketamine 1 Interferons 1 Interferon-alpha 1 Hypericum extract LI 160 1 Fentanyl 1 Dextromethorphan 1 Asian ginseng 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04116502 2024-11-18

MITHRIDATE

University of Birmingham

Phase 3 Recruiting

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon ⚡